Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRXRXRecursion Pharmaceuticals$3.12-4.4%$3.38$2.80▼$7.18$1.64B1.0516.51 million shs7.44 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRXRXRecursion Pharmaceuticals-1.81%-3.83%-1.06%-15.32%-24.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRXRXRecursion Pharmaceuticals$3.12-4.4%$3.38$2.80▼$7.18$1.64B1.0516.51 million shs7.44 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRXRXRecursion Pharmaceuticals-1.81%-3.83%-1.06%-15.32%-24.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRXRXRecursion Pharmaceuticals 2.20Hold$9.20195.35% UpsideCurrent Analyst Ratings BreakdownLatest RXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026RXRXRecursion Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.004/30/2026RXRXRecursion Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$11.00 ➝ $10.004/21/2026RXRXRecursion Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)2/26/2026RXRXRecursion Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.002/25/2026RXRXRecursion Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$7.00 ➝ $6.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRXRXRecursion Pharmaceuticals$65.74M24.99N/AN/A$2.14 per share1.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRXRXRecursion Pharmaceuticals-$644.76M-$1.20N/AN/AN/A-842.95%-54.33%-40.60%N/ALatest RXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026RXRXRecursion Pharmaceuticals-$0.30-$0.22+$0.08-$0.22$15.78 million$6.47 million2/25/2026Q4 2025RXRXRecursion Pharmaceuticals-$0.28-$0.21+$0.07-$0.21$24.56 million$35.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthRXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRXRXRecursion Pharmaceuticals0.015.475.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipRXRXRecursion Pharmaceuticals8.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableRXRXRecursion Pharmaceuticals400527.40 million485.23 millionOptionableRXRX HeadlinesRecent News About These CompaniesVanguard Group Inc. Grows Position in Recursion Pharmaceuticals, Inc. $RXRXMay 11 at 7:09 AM | marketbeat.comA Look At Recursion Pharmaceuticals (RXRX) Valuation After Clinical Updates And FDA DiscussionsMay 9 at 1:47 AM | finance.yahoo.comRecursion Pharmaceuticals (RXRX) Receives a Hold from Bank of America SecuritiesMay 8, 2026 | theglobeandmail.comRecursion Milestones Link AI Discovery To Clinical And Valuation UpsideMay 8, 2026 | finance.yahoo.comAchieve Life Sciences (NASDAQ:ACHV) versus Recursion Pharmaceuticals (NASDAQ:RXRX) Financial ComparisonMay 8, 2026 | americanbankingnews.comRecursion Pharmaceuticals: Q1 Earnings SnapshotMay 7, 2026 | chron.comRecursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $105,600.00 in StockMay 7, 2026 | marketbeat.comRecursion (RXRX) Q1 2026 Earnings TranscriptMay 7, 2026 | fool.comRecursion Pharmaceuticals (RXRX): Best AI Stocks Under $50 to Buy Right NowMay 7, 2026 | finance.yahoo.comRXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/YMay 7, 2026 | zacks.comRecursion Pharmaceuticals (NASDAQ:RXRX) Earns "Buy" Rating from Needham & Company LLCMay 7, 2026 | marketbeat.comRecursion Pharmaceuticals, Inc. (RXRX) Q1 2026 Earnings Call TranscriptMay 6, 2026 | seekingalpha.comRecursion Pharmaceuticals Q1 Earnings Call HighlightsMay 6, 2026 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Issues Quarterly Earnings ResultsMay 6, 2026 | marketbeat.comRecursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue EstimatesMay 6, 2026 | finance.yahoo.comRecursion Reports First Quarter Financial Results and Provides Business UpdateMay 6, 2026 | finance.yahoo.comRecursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue EstimatesMay 6, 2026 | zacks.comRecursion Reports First Quarter Financial Results and Provides Business UpdateMay 6, 2026 | globenewswire.comIs It Time To Reconsider Recursion Pharmaceuticals (RXRX) After Recent Share Price Swings?May 3, 2026 | finance.yahoo.comWhat Makes Recursion Pharmaceuticals, Inc. (RXRX) A Strong Penny StockMay 3, 2026 | finance.yahoo.comWhat Makes Recursion Pharmaceuticals, Inc. (RXRX) A Strong Penny StockMay 3, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRXRX Company DescriptionsRecursion Pharmaceuticals NASDAQ:RXRX$3.12 -0.15 (-4.45%) As of 12:42 PM Eastern This is a fair market value price provided by Massive. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
